Assan Aluminyum invests further in sustainable technologies
Assan Alüminyum, a subsidiary of the Kibar Group, continues its sustainable growth through a multi-year investment program. The program includes a brand new, energy efficient cold rolling line, as well as new continuous casting lines and improved filtration systems both for new and existing lines. Through these investments the company aims to enhance production efficiency through modernization, reduce its carbon footprint by increasing its share of renewable energy sources in energy consumption and boost its scrap aluminium usage in production, and ultimately expand its total annual production capacity by 60,000 tons. Upon completion of the investment program, the company aims to have the highest continuous casting capacity in all of
Assan Alüminyum received a green loan worth
Göksal Güngör, the General Manager of Assan Alüminyum noted, "We believe that aluminium holds a special place in the transition to a more sustainable future. Therefore, despite challenging market conditions, we will continue to invest in sustainable expansion. Sustainability is one of our core values at Assan Alüminyum, among reliability, flexibility and innovation. We are therefore fully committed to making our future plans in line with global sustainability principles and our sustainability motto of 'producing the future, without wasting it'. Our goal is to lead the way in sustainability-driven activities and initiatives across our industry."
Photo - https://mma.prnewswire.com/media/2347343/Assan_Aluminyum.jpg
Logo - https://mma.prnewswire.com/media/1088235/Assan_Aluminyum_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/assan-aluminyum-invests-further-in-sustainable-technologies-302071205.html
SOURCE Assan Aluminyum
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Victory Home Remodeling Ranked Among Selling Power Magazine's Top 60 Best Places to Sell in America
- New to The Street Show #761 to Broadcast Across Bloomberg U.S., Latin America and MENA, Featuring Sagtec Global, Virtuix, Lantern Pharma and YY Group
- Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share